ANP

6.35%

29.5¢

ANTISENSE THERAPEUTICS LIMITED

Market Cap $169.4M Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

ANP

Chart

71 72 73

20:17

4.3K

1.5M

20:17

Last post gino70

4.3K

1.5M

ANP

Ann: Positive feedback received on Paediatric Investigation Plan

2 3 4

10:22

220

58K

10:22

Last post PumpDumpChump1

220

58K

ANP

Where others have failed will Atl1102 succeed ?

16 17 18

08:48

1.0K

265K

08:48

Last post Uboy

1.0K

265K

ANP

Older data but interesting ..MS summary

25/10/21

16K

25/10/21

Last post hot001

16K

ANP

Sarepta and Nasdaq

15/10/21

3.0K

15/10/21

Last post itsagas

3.0K

ANP

Who funds trial - poll

15/10/21

8.7K

15/10/21

Last post Ressy

8.7K

ANP

Reddit page for ANP

13/10/21

1.4K

13/10/21

Last post shyaam1996

1.4K

ANP

Ann: Initial Director's Interest Notice

08/10/21

1.2K

08/10/21

Last post Suwang

1.2K

See All Discussions

Timeline

Initial Director's Interest Notice
08 Oct 09:19	Share

Antisense Therapeutics appoints new Non-Executive Director
04 Oct 09:17	Share

Positive feedback received on Paediatric Investigation Plan
30 Sep 09:47	Share

New data supports ATL1102s broader clinical potential
24 Sep 09:29	Share

ANP to present new proteomics data at WMS Congress 2021
20 Sep 09:37	Share

Appendix 4E and Full Year Statutory Accounts
25 Aug 17:42	Share

ANP to participate in development of DMD Guidance for FDA
24 Aug 08:31	Share

ANP Updates on US Regulatory Plans for ATL1102 in DMD
12 Aug 08:48	Share

Quarterly Report and Appendix 4C
29 Jul 09:28	Share

Antisense Therapeutics transitions to new Board Chair
28 Jul 09:06	Share

ANP and MCRI new R&D collaboration for ATL1102
28 Jun 09:56	Share

ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
22 Jun 09:09	Share

US FDA Feedback on Type C Meeting for ATL1102 in the US
01 Jun 09:58	Share

Manufacture of ATL1102 clinical supplies for Phase IIb trial
26 May 09:49	Share

Appendix 2A & Cleansing Notice
07 May 18:25	Share

Proposed issue of Securities - ANP
07 May 18:05	Share

Quarterly Report and Appendix 4C
28 Apr 09:54	Share

US FDA Type C Meeting for ATL1102 in DMD
23 Apr 09:51	Share

Initial Director's Interest Notice - CG
24 Mar 19:08	Share

Antisense Therapeutics appoints new Non-Executive Director
22 Mar 09:29	Share

Appendix 3G
19 Mar 19:58	Share

FDA Rare Disease Day 2021
04 Mar 08:56	Share

Jett Foundation 4th Annual Rare Disease Day
26 Feb 09:39	Share

ATL1102 DMD Paediatric Investigation Plan submitted to EMA
25 Feb 08:47	Share

Company Secretary Appointment
24 Feb 16:37	Share

Half Yearly Report and Half Year Accounts
24 Feb 16:30	Share

ANP meeting with US FDA granted for ATL1102 in DMD
15 Feb 09:04	Share

Quarterly Update and Appendix 4C
28 Jan 09:16	Share

Appendix 2A
15 Jan 16:45	Share

Proposed issue of Securities - ANP
15 Jan 16:25	Share

View More

(20min delay) Trade with IG
Last 29.5¢		Change -0.020(6.35%)		Mkt cap ! $169.4M

Open	High	Low	Value	Volume
32.0¢	32.0¢	29.0¢	$770.2K	2.533M

Buyers (Bids)

No.	Vol.	Price($)
5	126443	29.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.5¢	51314	2

View Market Depth

No.	Vol.	Price($)
5	126443	0.290
6	179074	0.285
7	137443	0.280
6	116740	0.275
6	165946	0.270

Price($)	Vol.	No.
0.295	51314	2
0.305	5000	1
0.315	71781	3
0.320	96503	3
0.325	80000	1

Last trade - 16.10pm 27/10/2021 (20 minute delay)

(live)
Last 29.0¢		Change -0.020 ( 6.81 %)
Open	High	Low	Volume
31.5¢	32.0¢	29.0¢	1414727
Last updated 15.59pm 27/10/2021 (live) ?

ANP (ASX) Chart

ANTISENSE THERAPEUTICS LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Timeline

Buyers (Bids)

Sellers (Offers)

Corporate Spotlight
Not Yet Available